A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

NCT01782131 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

585

Enrollment

INDUSTRY

Sponsor class

Conditions

Fungal Infections
Invasive Pulmonary Aspergillosis

Interventions

DRUG: Posaconazole
DRUG: Voriconazole
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC